# Fc engineering / effector function

Source: https://onco.cc/terms/fc-effector/  
OnCo record `fc-effector` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tweaking the antibody's tail to make it recruit immune cells more strongly, or not at all.

## Summary

Fc engineering means tweaking the antibody's tail, the Fc region, so that it recruits immune cells more strongly, or not at all. Afucosylation and Fc mutations enhance ADCC, whereas Fc-silencing through an IgG4 backbone or LALA mutations prevents unwanted immune activation in checkpoint inhibitors and T-cell engagers, and FcRn-binding mutations extend half-life. The term is linked to the Monoclonal antibodies and Bispecific antibodies technologies and to the terms Antibody, NK cell and Half-life. It is cited by the drug records for Margetuximab, Tislelizumab and Mogamulizumab, by the pathways on myeloid suppression, complement in cancer and NK-cell recognition, and by an idea on bispecific antibodies that engage macrophages instead of T cells.

## Fields

- Kind: Term
- Last checked: 2026-09-04

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Fragment_crystallizable_region
- Wikipedia: https://en.wikipedia.org/wiki/Fragment_crystallizable_region

## Connected records

- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Margetuximab](https://onco.cc/drugs/margetuximab/), [Mogamulizumab](https://onco.cc/drugs/mogamulizumab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- ideas: [Bispecific antibodies that engage macrophages instead of T cells](https://onco.cc/ideas/idea-bio2-myeloid-engager-bispecific/)
- terms: [Antibody](https://onco.cc/terms/antibody/), [Half-life](https://onco.cc/terms/half-life/), [NK cell](https://onco.cc/terms/nk-cell/)
- institutions: [University Hospital Southampton / Centre for Cancer Immunology](https://onco.cc/institutions/southampton-cancer/)
- pathways: [Complement in cancer](https://onco.cc/pathways/complement-in-cancer/), [Myeloid suppression: TAMs, MDSCs & don't-eat-me signals](https://onco.cc/pathways/myeloid-suppression-axis/), [NK-cell recognition: missing self & stress ligands](https://onco.cc/pathways/nk-cell-recognition/)

---
JSON: https://onco.cc/api/v1/entities/fc-effector.json